Kirby McInerney LLP Announces Class Action on Behalf of Eagle Pharmaceuticals, Inc. Investors

NEW YORK--()--The law firm of Kirby McInerney LLP announced today that it has filed class action lawsuit in the United States District Court for the District of New Jersey against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (Nasdaq: EGRX) and its CEO on behalf of all persons or entities who acquired Eagle Pharmaceuticals securities during the period from February 23, 2016 through March 18, 2016 (the "Class Period"). Pursuant to applicable law, investors have until 60 days from the date of this notice to file a motion to be appointed as lead plaintiff in the investor lawsuit, if they so choose.

The lawsuit alleges that throughout the Class Period the Company made misrepresentations about the FDA approval process for its new drug, Kangio™.

On March 18, 2016, the Company revealed that the FDA had issued a Complete Response Letter stating that it could not approve the drug application for Kangio in its current form and requesting further characterization of bivalirudin-related substances in the drug. The Company’s stock price declined materially in response.

If you acquired Eagle Pharmaceuticals securities during the Class Period and you are interested in learning more about this matter and any rights you might have with respect to these claims, contact Rona Li at securitiescases@kmllp.com, or by telephone at (212) 371-6600. Please bear in mind that some of these rights may be time-sensitive.

Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, whistleblower, antitrust and consumer litigation. The firm has specialized in complex litigation, including securities class actions, for several decades. Kirby McInerney LLP has repeatedly demonstrated its expertise in this field, and has been recognized by various courts that have appointed the firm to major positions in consolidated and multi-district litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars, and the firm's achievements and quality of service have been chronicled in numerous published decisions. Additional information about the firm or the claims against Eagle Pharmaceuticals, Inc. can be found at Kirby McInerney LLP's website: http://www.kmllp.com.

Contacts

Kirby McInerney LLP
Rona Li, (212) 371-6600
securitiescases@kmllp.com

Contacts

Kirby McInerney LLP
Rona Li, (212) 371-6600
securitiescases@kmllp.com